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1684-1182/Copyright ª 2015, TaiwanAbstract Background/Purpose: For extended-spectrum beta-lactamase (ESBL)-producing
Enterobacteriaceae infections, carbapenems are recommended as first line therapy, and clin-
ical data on the therapeutic efficacy of fluoroquinolones (FQs) is limited. This study compares
the efficacy of FQs and carbapenems for bloodstream infections caused by ESBL-producing Es-
cherichia coli or Klebsiella pneumoniae.
Methods: Between 2008 and 2010, adults with ESBL-producing E. coli or K. pneumoniae bacter-
emia at two medical centers were reviewed. Adults receiving definitive FQ or carbapenem
therapy were compared in a propensity score-matched analysis, and 30-day mortality was
the primary endpoint.
Results: A total of 299 patients were eligible. Patients receiving a FQ (n Z 24), either cipro-
floxacin or levofloxacin, had a lower 30-day mortality rate than those with carbapenem ther-
apy (8.3%, 2/24 vs. 23.3%, 64/275; p Z 0.12). Multivariate regression analysis revealed that a
critical illness [Pitt bacteremia score  4 points; odds ratio (OR), 7.09; p < 0.001], rapidly fatalt of Internal Medicine, National Cheng Kung University Hospital, Number 138, Sheng Li Road, 704,
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dx.doi.org/10.1016/j.jmii.2015.08.01underlying disease (OR, 5.73; p < 0.001), and hospital-associated infection (OR, 2.57;
p Z 0.01) were independently associated with 30-day mortality. By contrast, FQ definitive
therapy was a protective factor compared with carbapenems (OR, 0.18; pZ 0.04). There were
72 matched cases with carbapenem therapy in a propensity score-matched analysis, and a dif-
ference in the 30-day mortality rate of two groups was noted (8.3% vs. 29.2%; p Z 0.05).
Conslusion: For ESBL-producing E. coli or K. pneumoniae bacteremia, ciprofloxacin or levoflox-
acin, if active in vitro, can be considered as a carbapenem-sparing alternative.
Copyright ª 2015, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
In recent decades, nosocomial infections caused by
extended spectrum beta-lactamase (ESBL)-producers
became important issues,1 because such infections were
related to increased mortality and morbidity compared
with infections caused by susceptible organisms.2e4 A pre-
vious study demonstrated that third generation cephalo-
sporins resulted in a higher mortality rate than
carbapenems for treating ESBL-producing Enter-
obacteriaceae infections.5 Therefore, carbapenems have
been recommended as the drugs of choice for ESBL-
producing pathogen infections.6,7 However, increasing use
of carbapenems has been accompanied by the emergence
of carbapenem-resistant Enterobacteriaceae.8e10 There
are few studies reporting the role of carbapenem-sparing
regimens, such as cephamycins,11,12 beta-lactam/beta-
lactamase inhibitiors,13 or fluoroquinolones (FQs),5 in
treating ESBL-producing Enterobacteriaceae infections.
Although, the antibacterial activity of ciprofloxacin or lev-
ofloxacin was not affected by ESBL production,14 there was
increasing resistance to FQs among ESBL-producing Enter-
obacteriaceae isolates,15 arguing against empirical use of
FQs for ESBL-producer infections. Therefore, the purpose
of our study is to compare the therapeutic efficacy of FQs
and carbapenems for definitively treating bloodstream in-
fections caused by ESBL-producing Enterobacteriaceae.Methods
Study designs and patients
The study was conducted in two hospitals, National Cheng
Kung University Hospital in southern Taiwan and National
Taiwan University Hospital in northern Taiwan. Adults (age
>18 years) with ESBL-producing Escherichia coli or Klebsi-
ella pneumoniae bacteremia between 2008 and 2010 were
retrospectively reviewed. Eligible patients had to fulfill two
criteria: (1) the isolation of an ESBL producer alone in blood
culture(s), compatible with sepsis syndrome; and (2)
parenteral therapy with a FQ or carbapenem as definitive
therapy. Patients receiving more than one antibiotic as
definitive therapy were excluded. If patients experienced
more than one bacteremic episode, only the first episode
was included. The study was approved by the Institutional
Review Board of National Cheng Kung University Hospital
(ER-100-182).C-L, et al., Fluoroquinolone thera
i and Klebsiella pneumoniae, Jo
2The clinical choice of antibiotics was at the discretion of
the attending physicians. For patients with renal insuffi-
ciency, they received the following intravenous doses or
adjusted equivalents: 1 g every 24 hours for ertapenem,
0.5 g every 6 hours for imipenem, 1 g every 8 hours for
meropenem, 400 mg every 12 hours for ciprofloxacin, or
500 mg or 750 mg every 24 hours for levofloxacin. In both
hospitals, the prescriptions of carbapenems and FQs were
approved by infectious disease specialists and pharmacists
for their indication and dosage.
In vitro susceptibility and ESBL detection
ESBL production was detected with the phenotypic confir-
matory test recommended by the Clinical and Laboratory
Standards Institute.16 The minimum inhibitory concentra-
tions of carbapenems and FQs were determined with agar
dilution, and the interpretative breakpoints followed those
recommended by Clinical and Laboratory Standards Insti-
tute in 2013.16
Clinical evaluation and outcomes
Clinical information was retrieved from medical charts and
collected in a case record form. Bacteremia was defined as
the isolation of organisms in one or more separately ob-
tained blood culture with compatible clinical features.
Patients receiving a FQ or a carbapenem for > 48 hours
were included for assessment of outcome. The primary
outcome was 30-day mortality. Immunosuppression was
referred to as the receipt of corticosteroids (at least 10 mg
or an equivalent dosage daily) for > 2 weeks or of anti-
neoplastic or antirejection medication within 4 weeks
before the onset of bacteremia. The severity of the un-
derlying medical illness was stratified as being fatal, ulti-
mately fatal, or nonfatal.17 The severity of bacteremia on
the day of bacteremia onset was graded with the Pitt
bacteremia score.18
Statistical analysis
Data were analyzed with SPSS software for Windows,
version 17.0 (SPSS Inc., Chicago, IL, USA). Continuous var-
iables were expressed as mean values  standard deviation
and compared with the ManneWhitney U test or Student t
test. Categorical variables expressed as percentages of
case numbers were analyzed and compared with Fisher’s
exact test or Chi-square test. Independent predictors forpy for bloodstream infections caused by extended-spectrum beta-
urnal of Microbiology, Immunology and Infection (2015), http://
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regression analysis. Variables with p  0.1, as determined
using univariate analysis, were included in a multiple con-
ditioning logistic regression analysis. A Cox proportional
hazard model was used to compare survival in both groups,
adjusted for confounding variables. A p value < 0.05 was
considered statistically significant and all tests were two-
tailed.
The factors related to 30-day mortality estimated in
conditioning logistic regression analysis would be calcu-
lated as a propensity score for each case. Subsequently,
each patient receiving definitive FQ therapy (the case
group) was matched to three patients with definitive car-
bapenem therapy (the control group) with a similar pro-
pensity score. If there were more than three matches with
an identical propensity score, the one with a similar
immunosuppression condition (secondary matching vari-
able) or a similar age (a backup secondary matching vari-
able), would have a higher priority in the matching process.Results
A total of 398 patients with bacteremia caused by ESBL-
producing E. coli and K. pneumoniae were identified.
Among them, 24 (6.0%) cases, including 13 cases of E. coli
bacteremia and 11 of K. pneumoniae bacteremia, were
treated with a FQ, either ciprofloxacin or levofloxacin, for
> 48 hours and designated as the FQ group. There were 275
(69.1%) cases, including 103 cases of E. coli bacteremia and
172 of K. pneumoniae bacteremia, receiving one of three
carbapenems (ertapenem, imipenem, or meropenem) and
referred to as the carbapenem group. The characteristics of
the FQ group and carbapenem group are shown in Table 1.
There was no difference between age, comorbidity, hos-
pital onset, infection source, polymicrobial bacteremia,
severity of underlying disease, or severity of bacteremia.
However, there were more immunosuppressed patients in
the carbapenem group (19.6% vs. 0%, pZ 0.01). There was
a shorter time from bacteremia onset to appropriate anti-
microbial therapy in the FQ group than the carbapenem
group (0.88  1.4 days vs. 2.5  2.3 days; p Z 0.001).
Among these ESBL-producers, the susceptibility rate of
ciprofloxacin and levofloxacin was 28.9% (115 isolates) and
34.7% (138 isolates), respectively. In 260 levofloxacin-
nonsusceptible isolates, there was no isolate susceptible
to ciprofloxacin, but in 283 ciprofloxacin-nonsusceptible
isolates, there were 23 (8.1%) isolates susceptible to levo-
floxacin. To identify clinical variables predictive of sus-
ceptibility to ciprofloxacin and levofloxacin, a multivariate
analysis showed that only underlying chronic obstructive
pulmonary disease was significantly less likely to be sus-
ceptible to ciprofloxacin and levofloxacin [odds ratio (OR),
2.11; 95% confident interval (CI), 1.13e3.91; p Z 0.02;
Table 2].
While comparing the patients receiving appropriate
therapy earlier or later than 72 hours after bacteremia
onset, the 30-day mortality rate was similar (22.1% vs.
19.2%; pZ 0.53). The 14-day mortality rate (OR, 2.39; 95%
CI, 0.54e10.48; pZ 0.39), 30-day mortality rate (OR, 3.34;
95% CI, 0.76e14.57; pZ 0.12), or crude mortality rate (OR,
1.04; 95% CI, 0.44e2.47; pZ 1.0), was not different in thePlease cite this article in press as: Lo C-L, et al., Fluoroquinolone thera
lactamase-producing Escherichia coli and Klebsiella pneumoniae, Jo
dx.doi.org/10.1016/j.jmii.2015.08.012carbapenem and FQ groups (Table 1). In a multivariate
analysis, the presence of critical illness (a Pitt bacteremia
score  4 points; OR, 7.09; 95% CI, 3.71e13.56; p < 0.001),
and rapidly fatal underlying disease (OR, 5.73; 95% CI,
2.51e13.08; p < 0.001), and hospital onset infection (OR,
2.57; 95% CI, 1.22e5.45; p Z 0.01), were independently
associated with 30-day mortality, after adjustment of other
confounding variables (Table 3). By contrast, definitive FQ
therapy led to a better outcome while compared with
definitive carbapenem therapy (OR, 0.18; 95% CI,
0.03e0.92; p Z 0.04). Likewise, using the Cox regression
model, the FQ group tended to have a better outcome than
the carbapenem group (OR, 0.28; 95% CI, 0.07e1.14;
pZ 0.08; Figure 1). The survivors of the FQ group tended to
have a shorter hospital stay after bacteremia onset
(27.5  26.9 days vs. 52.0  77.5 days; p Z 0.14).
Twenty-four patients receiving definitive FQ therapy
were matched with the carbapenem group on the basis of
propensity score. Seventy-two matched patients had < 1%
difference in their propensity score. After adjustment for
confounding factors, including gender, condition of immu-
nosuppression, hospital-onset infection, rapidly fatal un-
derlying disease, and a Pitt bacteremia score  4 points,
there was a lower 30-day mortality rate in the FQ group
than that in the carbapenem group (OR, 4.53; 95% CI,
0.98e21.00; p Z 0.05).Discussion
ESBL-producing bacteria are typically associated with
multidrug resistance, since multiple resistance genes often
reside on the same plasmid.19 According to previous
studies, there was higher FQ minimum inhibitory concen-
trations in the ESBL-producer compared with those in non-
ESBL producers.15,20,21 In the present study, the suscepti-
bility rate of ciprofloxacin or levofloxacin in ESBL-producing
E. coli and K. pneumoniae bacteremia isolates was low,
29.1% and 34.7%, respectively. These figures were similar to
that in the UK (ciprofloxacin susceptibility in 17.8e28.7% of
Enterobacteriaceae),22 but was lower in South Korea (cip-
rofloxacin susceptibility in 55.4% of E. coli).23
In the present study, adults receiving definitive FQ
therapy had a better prognosis than those with carbapenem
therapy. There were few studies about the treatment ef-
ficacy of FQs in the infections caused by ESBL-producers.
The role of FQs in infections caused by ESBL-producers has
been mentioned in an in vitro study14 and a case series of
urinary tract infection caused by ESBL-producers.24 The
series of Kang et al,25 which included 117 cases comprising
E. coli or K. pneumoniae bloodstream infections, observed
that 30-day mortality rate of those receiving definitive
ciprofloxacin and carbapenem therapy was similar (10.3%
vs. 12.9%, respectively). This finding was compatible with
our results, that patients with definitive FQ therapy have a
noninferior or even better outcome compared with those
with definitive carbapenem therapy. However, in literature
there were contradictory data. Tumbarello et al26 demon-
strated ESBL-producing Enterobacteriaceae bacteremia
treated with FQ would be associated with a remarkable
high mortality rate, 50% in 16 cases, despite treated by
ciprofloxacin that was active in vitro. Besides, Endimianipy for bloodstream infections caused by extended-spectrum beta-
urnal of Microbiology, Immunology and Infection (2015), http://
Table 1 Characteristics of patients with bacteremia caused by extended-spectrum beta-lactamase-producing organisms
treated by a fluoroquinolone or a carbapenem.
Characteristics FQ group
N Z 24
Carbapenem group
N Z 275
Matched group
N Z 72
p a p b
Age (y) 70 (55e79) 70 (56e78) 71 (57e78) 0.86 0.65
Gender (male) 12 (50) 157 (57.1) 42 (58.3) 0.53 0.59
Hospital-onset bacteremia 16 (66.7) 194 (70.5) 49 (68.1) 0.65 1.0
Polymicrobial bacteremia 2 (8.3) 28 (10.2) 10 (13.9) 1.0 0.72
Source of bacteremia
Urosepsis 7 (29.2) 67 (24.4) 23 (31.9) 0.62 1.0
Pneumonia 6 (25) 75 (27.3) 17 (23.6) 1.0 1.0
Vascular catheter-related infection 5 (20.8) 49 (17.8) 10 (13.9) 0.78 0.52
Primary 3 (12.5) 39 (14.2) 13 (18.1) 1.0 0.75
Skin & soft tissue infection 1 (4.2) 20 (7.3) 3 (4.2) 1.0 1.0
Intra-abdominal infection 2 (8.3) 34 (12.4) 8 (11.1) 0.75 1.0
Central nervous system infection 0 (0) 2 (0.7) 0 (0) 1.0 c
Bone & joint infection 0 (0) 2 (0.7) 0 (0) 1.0
Comorbidity
Malignancy 9 (37.5) 93 (33.8) 29 (40.3) 0.82 1.0
Diabetes mellitus 9 (37.5) 123 (44.7) 42 (58.3) 0.53 0.10
Chronic kidney disease 6 (25) 106 (38.5) 22 (30.6) 0.27 0.80
Chronic dialysis 3 (12.5) 65 (23.6) 14 (19.4) 0.31 0.55
Liver cirrhosis 3 (12.5) 32 (11.6) 9 (12.5) 0.75 1.0
Chronic obstructive pulmonary disease 2 (8.3) 51 (18.5) 16 (22.2) 0.27 0.23
Old cerebrovascular accident 0 (0) 20 (7.3) 7 (9.7) 0.39 0.19
Congestive heart failure 0 (0) 15 (5.5) 4 (5.6) 0.62 0.57
Immunosuppression 0 (0) 54 (19.6) 1 (1.4) 0.01 1.0
Severity of underlying disease (McCabe classification)
Rapidly fatal 4 (16.7) 33 (12.0) 12 (16.7) 0.52 1.0
Pitt bacteremia score  4 8 (33.3) 89 (32.4) 25 (34.7) 1.0 1.0
Outcome
14-d morality 2 (8.3) 49 (17.8) 16 (22.2) 0.39 0.23
30-d mortality 2 (8.3) 64 (23.3) 21 (29.2) 0.12 0.05
Crude mortality 9 (37.5) 106 (38.5) 31 (43.1) 1.0 0.81
Data are presented as n (%) or media (interquartile range).
FQ Z fluoroquinolone.
a Crude analysis: fluoroquinolone group versus carbapenem group.
b Propensity score matched analysis: fluoroquinolone group versus matched carbapenem group.
c Ellipses indicate not available.
Table 2 Multivariate logistic regression analysis of the association among different variables and ciprofloxacin and levo-
floxacin susceptibility.
Variables Susceptible to ciprofloxacin
and levofloxacin
Univariate analysis Multivariate analysis
Yes, n Z 115 No, n Z 260 OR (95% CI) p OR (95% CI) p
Age (y) 66.4  16.3 67.3  16.2 a 0.65
Male 64 (55.7) 150 (57.9) 1.10 (0.70e1.71) 0.73
Diabetes mellitus 40 (34.8) 123 (47.3) 1.69 (1.07e2.66) 0.03 1.58 (1.00e2.50) 0.53
Chronic obstructive pulmonary disease 15 (13.0) 64 (24.6) 2.18 (1.18e4.01) 0.01 2.11 (1.13e3.91) 0.02
Liver cirrhosis 9 (7.8) 40 (15.4) 2.14 (1.00e4.58) 0.05 2.24 (1.04e4.82) 0.40
Old cerebrovascular accident 4 (3.5) 26 (10) 3.08 (1.05e9.05) 0.04 2.34 (0.77e7.09) 0.13
Data are presented as n (%) or mean  standard deviation.
CI Z confident interval; OR Z odds ratio.
a Ellipses indicate not available.
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Table 3 Multivariate logistic regression analysis of the associations among different variables and 30-day mortality in the
definitive therapy cohort.
Variables Survivors
N Z 233
Nonsurvivors
N Z 66
Univariate analysis Multivariate analysis
OR (95% CI) p OR (95% CI) p
Age (y) 67.0  16.6 67.7  16.4 a 0.46
Male 128 (54.9) 41 (62.1) 1.35 (0.77e2.36) 0.33
Hospital-onset bacteremia 157 (67.4) 53 (80.3) 1.97 (1.01e3.84) 0.05 2.57 (1.22e5.45) 0.01
Pneumonia 56 (24.0) 25 (37.9) 1.92 (1.08e3.45) 0.03 1.27 (0.65e2.48) 0.49
Urosepsis 68 (29.2) 6 (9.1) 0.24 (0.10e0.59) 0.001 0.47 (0.18e1.18) 0.12
Rapid fatal underlying disease 18 (7.7) 19 (28.8) 4.83 (2.36e9.90) <0.001 5.73 (2.51e13.08) <0.001
Pitt bacteremia score  4 points 55 (23.6) 42 (63.6) 5.67 (3.15e10.17) <0.001 7.09 (3.71e13.56) <0.001
Fluoroquinolone definitive therapy 22 (9.4) 2 (3.0) 0.30 (0.07e1.31) 0.12 0.18 (0.03e0.92) 0.04
Data are presented as n (%) or mean  standard deviation.
CI Z confident interval; OR Z odds ratio.
a Ellipses indicate not available.
Figure 1. Cox proportional hazard model for survival anal-
ysis for patients with bacteremia due to extended-spectrum
beta-lactamase-producing Escherichia coli or Klebsiella pneu-
moniae, categorized by definitive fluoroquinolone (n Z 24,
solid line) and carbapenem therapy (nZ 275, dotted line; odds
ratio, 0.28; 95% confidence interval, 0.07e1.14; p Z 0.08).
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+ MODELet al27 reported that 21 patients with ESBL-producing,
ciprofloxacin-susceptible K. pneumoniae bacteremia, and
found there was more treatment failure for patients
receiving ciprofloxacin than those treated with imipenem
(71.4% vs. 20%; p Z 0.03).
Although a better outcome of FQ therapy favors their
clinical use, our retrospective cohort remained to be
inherently biased in two comparative groups. Those in the
carbapenem group received appropriate antimicrobial
therapy later than those in the FQ group. Previous studies
showed that inadequate initial antimicrobial therapy was
related to a poor outcome.26,28 By contrast, Kang et al25
showed that in patients receiving appropriate definitive
carbapenem or ciprofloxacin therapy, no difference was
noted in the 30-day mortality rate between those receiving
inappropriate (n Z 37) and appropriate (n Z 58) empiricalPlease cite this article in press as: Lo C-L, et al., Fluoroquinolone thera
lactamase-producing Escherichia coli and Klebsiella pneumoniae, Jo
dx.doi.org/10.1016/j.jmii.2015.08.012therapy (18.9% vs. 15.5%; p Z 0.66). Similarly, Rodrı´guez-
Ban˜o et al29 reported that those with empirical inappro-
priate and appropriate antimicrobial therapy had a similar
14-day (26% vs. 25%, respectively) or 30-day mortality rate
(30% vs. 30%, respectively). These findings were consistent
with our result, that a delay in prescribing appropriate
therapy for 72 hours after bacteremia onset was not related
to a poor outcome, suggestive of a therapeutic benefit of
FQ treatment.
The nonsusceptible rate of ciprofloxacin (70.9%) was
higher than that of levofloxacin (65.3%) in this study, and
such a finding is compatible with the earlier concept that
ciprofloxacin would be more easily affected by mutations in
GyrA, a subunit of DNA gyrase, than levofloxacin.30 Besides,
ciprofloxacin resistance can be caused by other mecha-
nisms, including modifying enzymes, DNA gyrase or topo-
isomerase, and plasmid-mediated efflux pump.31 Host-
related risk factors of FQ resistance, including residence
in long-term care facilities, older age, and neurologic dis-
ease, were well recognized, and previous exposure to
several classes of antibiotics, aminoglycosides, FQs, or
third-generation cephalosporins, were often regarded as
risk factors.23,32,33 A novel host factor, chronic obstructive
pulmonary disease, identified in the study, could be
explained by more antibiotic exposure due to frequent
hospitalizations for acute exacerbation of underlying pul-
monary illness.
There were several limitations in our study. Firstly, we
only included bloodstream infections due to E. coli and K.
pneumoniae, two major Enterobacteriaceae pathogens.
These results cannot be explored to the infections due to
other species of the Enterobacteriaceae family. Secondly,
although the case number of definitive FQ therapy is
limited, that cannot make the difference in crude or sepsis-
related mortality rate significant. The individuals in the FQ
group and matched carbapenem group were comparable in
terms of demographic characteristic and severity of illness.
In addition, the primary outcome is better for the FQ group
patients than the group receiving any carbapenem as the
definitive therapy. Likewise, a similar finding was noted in
the multivariate logistic regression analysis. More clinical
data are warranted to verify the role of FQ therapy for
ESBL-producer bacteremia. Thirdly, only hospitalizationpy for bloodstream infections caused by extended-spectrum beta-
urnal of Microbiology, Immunology and Infection (2015), http://
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available. It remains undetermined if there is no difference
in long-term outcome between two study groups.
In conclusion, for adults with bacteremia due to ESBL-
producing E. coli and K. pneumoniae, against which cipro-
floxacin or levofloxacin is active in vitro, either can be
regarded as one of the regimens of choice.Conflicts of interest
The authors have no conflicts of interest to declare.References
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